HK1124869A1 - Egln2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases egln2 - Google Patents

Egln2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases egln2

Info

Publication number
HK1124869A1
HK1124869A1 HK09102652.6A HK09102652A HK1124869A1 HK 1124869 A1 HK1124869 A1 HK 1124869A1 HK 09102652 A HK09102652 A HK 09102652A HK 1124869 A1 HK1124869 A1 HK 1124869A1
Authority
HK
Hong Kong
Prior art keywords
egln2
preventing
coronary heart
variants
heart diseases
Prior art date
Application number
HK09102652.6A
Other languages
English (en)
Inventor
Detlef Kozian
Matthias Herrmann
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HK1124869A1 publication Critical patent/HK1124869A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK09102652.6A 2005-10-12 2009-03-19 Egln2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases egln2 HK1124869A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005048898A DE102005048898A1 (de) 2005-10-12 2005-10-12 EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
PCT/EP2006/009518 WO2007042166A2 (de) 2005-10-12 2006-09-30 Egln2-varianten und ihre verwendung bei der vorbeugung oder behandlung thromboembolischer erkrankungen und koronarer herzerkrankungen

Publications (1)

Publication Number Publication Date
HK1124869A1 true HK1124869A1 (en) 2009-07-24

Family

ID=37773569

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09102652.6A HK1124869A1 (en) 2005-10-12 2009-03-19 Egln2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases egln2

Country Status (14)

Country Link
US (3) US8114398B2 (ko)
EP (1) EP1937714B1 (ko)
JP (1) JP5210166B2 (ko)
KR (1) KR101320333B1 (ko)
CN (1) CN101282988B (ko)
AR (1) AR055442A1 (ko)
AU (1) AU2006301579B2 (ko)
BR (1) BRPI0617304A2 (ko)
CA (1) CA2625613A1 (ko)
DE (1) DE102005048898A1 (ko)
HK (1) HK1124869A1 (ko)
IL (2) IL190586A0 (ko)
TW (1) TWI404725B (ko)
WO (1) WO2007042166A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017033181A1 (en) 2015-08-24 2017-03-02 My Size Israel 2014 Ltd. A system for and a method of measuring using a handheld electronic device

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
US5698765A (en) 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) * 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
JP3741447B2 (ja) * 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−１遺伝子の機能が欠損したマウス
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
NZ332033A (en) 1996-03-25 1999-09-29 Lohmann Therapie Syst Lts Transdermal therapeutic system (tts) with small application-area thickness and great flexibility, and production process
DE19625049A1 (de) 1996-06-22 1998-01-02 Inst Pflanzengenetik & Kultur Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
WO2002074981A2 (en) * 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US6566088B1 (en) * 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
CA2510895A1 (en) * 2002-12-20 2004-07-15 Applera Corporation Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
EP2474632B1 (en) * 2002-12-20 2015-08-12 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
DE102005048899A1 (de) * 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Diagnose thromboembolischer Erkrankungen und koronarer Herzerkrankungen

Also Published As

Publication number Publication date
AU2006301579B2 (en) 2012-03-01
EP1937714A2 (de) 2008-07-02
US8211427B2 (en) 2012-07-03
KR20080052663A (ko) 2008-06-11
JP2009511027A (ja) 2009-03-19
DE102005048898A1 (de) 2007-04-19
US8114398B2 (en) 2012-02-14
US20110123515A1 (en) 2011-05-26
CN101282988B (zh) 2012-08-22
WO2007042166A8 (de) 2012-10-26
EP1937714B1 (de) 2013-08-14
BRPI0617304A2 (pt) 2011-07-19
IL220636A0 (en) 2012-08-30
US8329167B2 (en) 2012-12-11
CA2625613A1 (en) 2007-04-19
TW200738746A (en) 2007-10-16
AU2006301579A1 (en) 2007-04-19
JP5210166B2 (ja) 2013-06-12
IL190586A0 (en) 2008-11-03
AR055442A1 (es) 2007-08-22
KR101320333B1 (ko) 2013-10-22
TWI404725B (zh) 2013-08-11
US20090220479A1 (en) 2009-09-03
WO2007042166A3 (de) 2007-08-02
CN101282988A (zh) 2008-10-08
US20120096571A1 (en) 2012-04-19
WO2007042166A2 (de) 2007-04-19

Similar Documents

Publication Publication Date Title
IL189578A0 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
HK1117154A1 (en) Benzoquinazoline derivatives and their use in treating bone disorders
HK1207661A1 (en) Aptamer therapeutics useful in the treatment of complement related disorders
SG127661A1 (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
LT2390255T (lt) Nauji aminoglikozidai ir jų panaudojimas genetinių sutrikimų gydyme
IL183772A0 (en) Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
IL188420A0 (en) Methods and compositions with enhanced therapeutic activity
ZA200702421B (en) Iron complex for use in the treatment and/or prevention of nutritional disorders
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
ME01219B (me) Alfa-aminoamid derivati korisni u liječenju bolesti zavisnosti
HK1103282A1 (en) Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1765331A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
IL179560A0 (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
GB2460976B (en) Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
EP1744761A4 (en) METHOD FOR THE TREATMENT OR PREVENTION OF RESTENOSIS AND OTHER PROLIFERATIVE VASCULAR DISORDER
ZA200610297B (en) Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias
IL220636A0 (en) Egln2 variants and use thereof in preventing or treating thromboembolic disorders and coronary heart diseases
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
GB0509911D0 (en) Medical treatment aid for use in treating children
ZA200801548B (en) Pyridine derivatives and their use in the treatment of psychotic disorders
IL177062A0 (en) Use of 14, 15 - dihydro- 20,21 - dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders
IL244653A0 (en) New amino-sugars and their use for the treatment of genetic diseases
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
IL229577A (en) Amino-sugars and their use to treat genetic diseases
GB0512551D0 (en) Methods and therapeutic treatments

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160930